Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB).

“Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience in breast cancer to Rna Diagnostics,” said Jeremy Bridge-Cook, President and CEO of Rna Diagnostics Inc. “We are delighted to have him join our Clinical Advisory Board.”

Dr Goetz is a clinician in the Division of Medical Oncology at Mayo Clinic in Rochester, Minnesota and a Professor of Oncology and Pharmacology at Mayo Clinic. He is chair of the Mayo Clinic Breast Cancer Research Group, Co-leader of the Mayo Clinic Women’s Cancer Program, and Co-leader of the Mayo Clinic Breast Cancer SPORE.

The RNA Disruption Assay™ (RDA™) is a diagnostic test that measures tumor response to treatment after the 1st cycle (14-21 days) of neoadjuvant chemotherapy (drug treatment prior to surgery).  Rna Diagnostics recently announced the launch of an international prospective clinical trial to validate RDA as a tool for assessing primary breast cancer treatment efficacy. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will evaluate the ability of RDA to predict treatment efficacy in a cohort of  600 patients with primary breast cancer, scheduled to receive neoadjuvant chemotherapy. Approximately 40 centers across North America and Europe will participate in BREVITY. The Clinical Advisory Board has been assisting in finalizing the BREVITY trial design and protocol.